NEW YORK (GenomeWeb News) - Biocrates Life Sciences has joined a European Union project to find diagnostic biomarkers for colon and breast cancer, the company said today.
Biocrates, based in Innsbruck, Austria, said that it will perform metabolomics services for the study, called COBRED for Colon and Breast cancer Diagnostics.
The company said it will use its TargetIDQ metabolomics platform to identify and quantify more than 1,000 metabolites in the study.
The study is funded by the EU’s Sixth Framework program and involves eight partners from France, Hungary, Estonia, and Austria. The goal of the study is to discover biomarkers to assess the risk of cancer recurrence after initial tumor removal.